首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.
【24h】

Good research practices for comparative effectiveness research: defining, reporting and interpreting nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report--Part I.

机译:相对有效性研究的良好研究实践:使用辅助数据源定义,报告和解释治疗效果的非随机研究:ISPOR回顾性数据库分析任务组报告的良好研究实践-第一部分。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: Health insurers, physicians, and patients worldwide need information on the comparative effectiveness and safety of prescription drugs in routine care. Nonrandomized studies of treatment effects using secondary databases may supplement the evidence based from randomized clinical trials and prospective observational studies. Recognizing the challenges to conducting valid retrospective epidemiologic and health services research studies, a Task Force was formed to develop a guidance document on state of the art approaches to frame research questions and report findings for these studies. METHODS: The Task Force was commissioned and a Chair was selected by the International Society for Pharmacoeconomics and Outcomes Research Board of Directors in October 2007. This Report, the first of three reported in this issue of the journal, addressed issues of framing the research question and reporting and interpreting findings. RESULTS: The Task Force Report proposes four primary characteristics-relevance, specificity, novelty, and feasibility while defining the research question. Recommendations included: the practice of a priori specification of the research question; transparency of prespecified analytical plans, provision of justifications for any subsequent changes in analytical plan, and reporting the results of prespecified plans as well as results from significant modifications, structured abstracts to report findings with scientific neutrality; and reasoned interpretations of findings to help inform policy decisions. CONCLUSIONS: Comparative effectiveness research in the form of nonrandomized studies using secondary databases can be designed with rigorous elements and conducted with sophisticated statistical methods to improve causal inference of treatment effects. Standardized reporting and careful interpretation of results can aid policy and decision-making.
机译:目的:全世界的健康保险公司,医生和患者都需要有关处方药在常规护理中的相对有效性和安全性的信息。使用二级数据库进行治疗效果的非随机研究可能会补充来自随机临床试验和前瞻性观察研究的证据。认识到进行有效的回顾性流行病学和卫生服务研究所面临的挑战,成立了一个工作队,以制定有关研究问题框架和报告这些研究结果的最新方法的指导文件。方法:2007年10月,国际药物经济学和结果研究理事会任命了工作组,并任命了主席。本报告是本期杂志的三期中的第一期,旨在解决研究问题的框架问题。以及报告和解释发现。结果:工作组报告提出了四个主要特征:相关性,特异性,新颖性和可行性,同时定义了研究问题。建议包括:研究问题的先验规范的实践;预定分析计划的透明度,为分析计划中的任何后续更改提供理由,并报告预定计划的结果以及重大修改的结果,以科学的中性方式报告发现的结构化摘要;以及对结果的合理解释,有助于为政策决策提供依据。结论:可以使用严格的要素设计采用二级数据库的非随机研究形式的比较有效性研究,并使用复杂的统计方法进行研究,以改善治疗效果的因果关系。标准化的报告和对结果的仔细解释可以帮助制定政策和决策。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号